“A Randomized, Double-Blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s94, https://doi.org/10.25251/skin.5.supp.94.